# SPINRAZA Administration and Dosing Information

Keywords: SPINRAZA, intrathecal injection, cerebrospinal fluid, SMA, SMN protein, dosing, maintenance dose, adverse events

> This page provides detailed information about SPINRAZA, including its administration method, dosing schedule, and considerations for treating spinal muscular atrophy (SMA). It also includes guidelines for delayed or missed doses and adverse event reporting.

## Details

- [Administration](#): SPINRAZA is administered intrathecally via lumbar puncture into the cerebrospinal fluid to target the central nervous system directly.
- [Mechanism of Action](#): SPINRAZA addresses the underlying cause of motor neuron loss in SMA by increasing functional SMN protein levels.
- [Dosing Information](#): The recommended dosage is 12 mg per administration, consisting of four loading doses followed by maintenance doses every four months.
- [Delayed or Missed Doses](#): Provides specific recommendations for adjusting dosing schedules based on the time elapsed since the last dose.
- [Treatment Considerations](#): Treatment initiation and continuation should be individualized, balancing expected benefits and risks, especially in severe cases of SMA.
- [Adverse Event Reporting](#): Adverse events can be reported via national health authorities or directly to Biogen through provided contact details.
- [References](#): Includes citations for SPINRAZA's summary of product characteristics and relevant studies.